Lewis E. Pennicott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lewis E. Pennicott has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Keith W. Caldecott
Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, UK
3 shared publications - Simon E. Ward
Medicines Discovery Institute, Cardiff University, Cardiff, UK
3 shared publications Adrian Highton
Department of Chemistry, The University of Sussex, Falmer, Brighton BN1 9QJ, U.K., Pfizer Pharmaceuticals Limited, Sandwich, Kent CT13 9NJ, U.K., and AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.
2 shared publicationsCharles Z. Ding
2 shared publicationsDazhong Fan
2 shared publicationsEmilia Komulainen
Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 1 April 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (8) , 127040
Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer
- 1 April 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (8) , 127040
Open AccessDevelopment of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer
- 16 May 2019
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 14 (6) , 1110-1114
Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux
Tyrosyl DNA phosphodiesterase 2 (TDP2) facilitates the repair of topoisomerase II (TOP2)-linked DNA double-strand breaks and, as a consequence, is required for cellular resistance to TOP2 “poisons”. Recently, a deazaflavin series of compounds were identified as potent inhibitors of TDP2, in vitro. Here, however, we show that while some deazaflavins can induce cellular sensitivity to the TOP2 poison etoposide, they do so independently of TDP2 status. Consistent with this, both the cellular level of etoposide-induced TOP2 cleavage complexes and the intracellular concentration of etoposide was increased by incubation with deazaflavin, suggesting an impact of these compounds on etoposide uptake/efflux. In addition, deazaflavin failed to increase the level of TOP2 cleavage complexes or sensitivity induced by m-AMSA, which is a different class of TOP2 poison to which TDP2-defective cells are also sensitive. In conclusion, while deazaflavins are potent inhibitors of TDP2 in vitro, their limited cell permeability and likely interference with etoposide influx/efflux limits their utility in cells.
- 16 May 2019
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 14 (6) , 1110-1114
Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux
Tyrosyl DNA phosphodiesterase 2 (TDP2) facilitates the repair of topoisomerase II (TOP2)-linked DNA double-strand breaks and, as a consequence, is required for cellular resistance to TOP2 “poisons”. Recently, a deazaflavin series of compounds were identified as potent inhibitors of TDP2, in vitro. Here, however, we show that while some deazaflavins can induce cellular sensitivity to the TOP2 poison etoposide, they do so independently of TDP2 status. Consistent with this, both the cellular level of etoposide-induced TOP2 cleavage complexes and the intracellular concentration of etoposide was increased by incubation with deazaflavin, suggesting an impact of these compounds on etoposide uptake/efflux. In addition, deazaflavin failed to increase the level of TOP2 cleavage complexes or sensitivity induced by m-AMSA, which is a different class of TOP2 poison to which TDP2-defective cells are also sensitive. In conclusion, while deazaflavins are potent inhibitors of TDP2 in vitro, their limited cell permeability and likely interference with etoposide influx/efflux limits their utility in cells.
- Top Cited PapersOpen Access
- 1 July 2018
- Published by Elsevier in Molecular Cell
- Vol. 71 (2) , 319-331.e3
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- 1 July 2018
- Published by Elsevier in Molecular Cell
- Vol. 71 (2) , 319-331.e3
Top Cited PapersOpen AccessThe Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- Open Access
- 21 January 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (4) , 592-604
Toward More Drug Like Inhibitors of Trypanosome Alternative Oxidase
New tools are required to ensure the adequate control of the neglected tropical disease human African trypanosomia-sis. Annual reports of infection have recently fallen to fewer than 5000 cases per year; however, current therapies are hard to administer and have safety concerns, hence are far from ideal. Trypanosome alternative oxidase is an exciting target for controlling the infection; it is unique to the parasite and inhibition of this enzyme with the natural product ascofuranone has shown to clear in vivo infections. We report the synthesis and associated structure activity relation-ships of inhibitors based upon this natural product with correlation to T. b. brucei growth inhibition in an attempt to generate molecules that possess improved physicochemical properties and potential for use as new treatments for human African trypanosomiasis.
- 21 January 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (4) , 592-604
Open AccessToward More Drug Like Inhibitors of Trypanosome Alternative Oxidase
New tools are required to ensure the adequate control of the neglected tropical disease human African trypanosomia-sis. Annual reports of infection have recently fallen to fewer than 5000 cases per year; however, current therapies are hard to administer and have safety concerns, hence are far from ideal. Trypanosome alternative oxidase is an exciting target for controlling the infection; it is unique to the parasite and inhibition of this enzyme with the natural product ascofuranone has shown to clear in vivo infections. We report the synthesis and associated structure activity relation-ships of inhibitors based upon this natural product with correlation to T. b. brucei growth inhibition in an attempt to generate molecules that possess improved physicochemical properties and potential for use as new treatments for human African trypanosomiasis.
- Open Access
- 1 December 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 141, 676-689
African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase
- 1 December 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 141, 676-689
Open AccessAfrican trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase
- Open Access
- 28 June 2016
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 473 (13) , 1869-1879
Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2
Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a 5′-tyrosyl DNA phosphodiesterase important for the repair of DNA adducts generated by non-productive (abortive) activity of topoisomerase II (TOP2). TDP2 facilitates therapeutic resistance to topoisomerase poisons, which are widely used in the treatment of a range of cancer types. Consequently, TDP2 is an interesting target for the development of small molecule inhibitors that could restore sensitivity to topoisomerase-directed therapies. Previous studies identified a class of deazaflavin-based molecules that showed inhibitory activity against TDP2 at therapeutically useful concentrations, but their mode of action was uncertain. We have confirmed that the deazaflavin series inhibits TDP2 enzyme activity in a fluorescence-based assay, suitable for high-throughput screen (HTS)-screening. We have gone on to determine crystal structures of these compounds bound to a ‘humanized’ form of murine TDP2. The structures reveal their novel mode of action as competitive ligands for the binding site of an incoming DNA substrate, and point the way to generating novel and potent inhibitors of TDP2.
- 28 June 2016
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 473 (13) , 1869-1879
Open AccessMode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2
Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a 5′-tyrosyl DNA phosphodiesterase important for the repair of DNA adducts generated by non-productive (abortive) activity of topoisomerase II (TOP2). TDP2 facilitates therapeutic resistance to topoisomerase poisons, which are widely used in the treatment of a range of cancer types. Consequently, TDP2 is an interesting target for the development of small molecule inhibitors that could restore sensitivity to topoisomerase-directed therapies. Previous studies identified a class of deazaflavin-based molecules that showed inhibitory activity against TDP2 at therapeutically useful concentrations, but their mode of action was uncertain. We have confirmed that the deazaflavin series inhibits TDP2 enzyme activity in a fluorescence-based assay, suitable for high-throughput screen (HTS)-screening. We have gone on to determine crystal structures of these compounds bound to a ‘humanized’ form of murine TDP2. The structures reveal their novel mode of action as competitive ligands for the binding site of an incoming DNA substrate, and point the way to generating novel and potent inhibitors of TDP2.
- 1 March 2015
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 7 (4) , 473-491
AMPA Receptor-Positive Allosteric Modulators for the Treatment of Schizophrenia: An Overview of Recent Patent Applications
The role of glutamate and its receptors in central nervous system biology and disease has long been of interest to scientists involved in both fundamental research and drug discovery, however the complex pharmacology and lack of highly selective compounds has severely hampered drug discovery efforts in this area. Recent advances in the identification and profiling of positive allosteric modulators of the AMPA receptor offer a potential way forward and the hope of a new treatment for schizophrenia. This article will review recent patent applications published in this area.
- 1 March 2015
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 7 (4) , 473-491
AMPA Receptor-Positive Allosteric Modulators for the Treatment of Schizophrenia: An Overview of Recent Patent Applications
The role of glutamate and its receptors in central nervous system biology and disease has long been of interest to scientists involved in both fundamental research and drug discovery, however the complex pharmacology and lack of highly selective compounds has severely hampered drug discovery efforts in this area. Recent advances in the identification and profiling of positive allosteric modulators of the AMPA receptor offer a potential way forward and the hope of a new treatment for schizophrenia. This article will review recent patent applications published in this area.
- 1 October 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (19) , 5695-5700
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates
- 1 October 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (19) , 5695-5700
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates
- 1 June 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (12) , 3550-3556
Synthesis and evaluation of novel α-amino cyclic boronates as inhibitors of HCV NS3 protease
- 1 June 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (12) , 3550-3556
Synthesis and evaluation of novel α-amino cyclic boronates as inhibitors of HCV NS3 protease
- 24 October 2007
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 72 (24) , 9387-9390
A Total Synthesis of Galbonolide B
An ester enolate rearrangement/silicon mediated fragmentation cascade was used to convert 7 and 8 into the alcohol 9. The alcohol 9 was converted into the allylic alcohol 12 and then to the ester 14. A further ester enolate rearrangement furnished the stereochemical identity of galbonolide B 1. Base mediated macrocyclization of the acetate ester 16 followed by base mediated alkylation and acetal deprotection gave galbonolide B 1.
- 24 October 2007
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 72 (24) , 9387-9390
A Total Synthesis of Galbonolide B
An ester enolate rearrangement/silicon mediated fragmentation cascade was used to convert 7 and 8 into the alcohol 9. The alcohol 9 was converted into the allylic alcohol 12 and then to the ester 14. A further ester enolate rearrangement furnished the stereochemical identity of galbonolide B 1. Base mediated macrocyclization of the acetate ester 16 followed by base mediated alkylation and acetal deprotection gave galbonolide B 1.